Eledon Pharmaceuticals, Inc.: diluted weighted-average shares

What this measure means

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Eledon Pharmaceuticals uses the two-class method to allocate losses between common stock and Series X/Series X1 preferred stock. Its 2024 and 2025 common EPS use reported common-stock losses of $31.992 million and $42.328 million, rather than the total losses. Dollar amounts are in thousands, but shares and EPS are unscaled. Basic weighted-average shares already include 12,443,755 and 36,629,572 prefunded-warrant shares, respectively, because their exercise price is nominal. Other potential instruments are excluded during losses. This note preserves the reported class allocations without reconstructing a conversion or weighting formula. Read the source filing.

Selected filing history

Related financial histories

• Eledon Pharmaceuticals, Inc.: total assets
• Eledon Pharmaceuticals, Inc.: total liabilities
• Eledon Pharmaceuticals, Inc.: stockholders equity
• Eledon Pharmaceuticals, Inc.: cash and cash equivalents
• Eledon Pharmaceuticals, Inc.: net income or loss
• Eledon Pharmaceuticals, Inc.: operating cash flow
• Eledon Pharmaceuticals, Inc.: capital expenditure payments
• Eledon Pharmaceuticals, Inc.: financing cash flow
• Eledon Pharmaceuticals, Inc.: investing cash flow
• Eledon Pharmaceuticals, Inc.: retained earnings or deficit
• Eledon Pharmaceuticals, Inc.: basic weighted-average shares
• Eledon Pharmaceuticals, Inc.: basic earnings per share
• Eledon Pharmaceuticals, Inc.: diluted earnings per share
• Eledon Pharmaceuticals, Inc.: income tax expense or benefit
• Eledon Pharmaceuticals, Inc.: net property, plant and equipment
• Eledon Pharmaceuticals, Inc.: share-based compensation expense
• Eledon Pharmaceuticals, Inc.: operating income or loss
• Eledon Pharmaceuticals, Inc.: current assets
• Eledon Pharmaceuticals, Inc.: current liabilities
• Eledon Pharmaceuticals, Inc.: current accounts payable
• Eledon Pharmaceuticals, Inc.: goodwill carrying amount
• Eledon Pharmaceuticals, Inc.: operating expenses
• Eledon Pharmaceuticals, Inc.: research and development expense

Inspect the source

Entity

Eledon Pharmaceuticals, Inc. / CIK 0001404281

Captured

2026-09-20T08:00:59.875Z

SEC response SHA-256

4f5cc5be1669d2394918add4693809b2004c1033ce5e8c4625a2a4da5c2f19a1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001404281.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))